Lyell Immunopharma (LYEL) Current Assets (2020 - 2026)

Lyell Immunopharma's Current Assets history runs 7 years deep, the most recent figure standing at $267.3 million for Q1 2026.

• In Q1 2026, Current Assets fell 13.54% year-over-year to $267.3 million; the TTM figure through Mar 2026 stood at $267.3 million (down 13.54% YoY), while the FY2025 annual figure was $260.9 million, down 31.26% from the prior year.
• Current Assets came in at $267.3 million for Q1 2026 at Lyell Immunopharma, up from $260.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $666.8 million in Q2 2022 to a low of $260.9 million in Q4 2025.
• A 5-year average of $487.5 million and a median of $534.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets advanced 4.53% in 2022 and plunged 43.54% in 2025, its largest moves.
• Lyell Immunopharma's Current Assets stood at $651.3 million in 2022, then dropped by 14.83% to $554.7 million in 2023, then sank by 31.57% to $379.6 million in 2024, then sank by 31.26% to $260.9 million in 2025, then climbed by 2.44% to $267.3 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $267.3 million, $260.9 million, and $328.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison